Using commercially available Ca2+ inhibitors/modulators, we identified that SOCs were the most attractive targets for regulating dystrophin deficiency-mediated Ca2+ overload. Here, CISH is linked to neuromuscular disease caused by qualitative or quantitative defects of dystrophin.